Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Submission Forms
Promote Your Event
Place an Ad
Weather
News
Local News
Sports
Obituaries
Local Events
Photo Galleries
Video Gallery
e-Edition
Classifieds
Place an ad
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
15.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 26, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
15.00
Bid (Size)
12.00 (1)
Ask (Size)
18.97 (2)
Prev. Close
15.00
Today's Range
15.00 - 15.00
52wk Range
14.95 - 62.08
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
May 26, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Analyst Ratings for Bicycle Therapeutics
May 23, 2022
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Performance
YTD
-74.79%
-74.79%
1 Month
-36.97%
-36.97%
3 Month
-67.05%
-67.05%
6 Month
-72.53%
-72.53%
1 Year
-50.25%
-50.25%
More News
Read More
Expert Ratings for Bicycle Therapeutics
May 06, 2022
Via
Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
May 05, 2022
Via
Benzinga
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Where Bicycle Therapeutics Stands With Analysts
April 13, 2022
Via
Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
April 08, 2022
Via
Benzinga
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
April 13, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
April 13, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 11, 2022
Via
Benzinga
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 11, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Via
Benzinga
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
April 08, 2022
Via
Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
April 08, 2022
Via
Benzinga
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
April 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics's Return On Capital Employed Overview
March 04, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
March 03, 2022
Via
Benzinga
Bicycle Therapeutics: Q4 Earnings Insights
March 01, 2022
Via
Benzinga
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
January 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
February 14, 2022
Via
Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
December 31, 2021
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
December 17, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.